SITC 2023 | Decoding sip-T’s specificity of action and efficacy with IL-15

Russell Pachynski, MD, Washington University School of Medicine, St Louis, MO, provides an overview of his presentation on Sipuleucel-T (sip-T) plus IL-15 treatment for metastatic castration-resistant prostate cancer (mCRPC). Whilst sip-T is an approved immunotherapy, its mechanism of action is poorly characterized; by collecting the residue post-reinfusion of sip-T treated immune cells, Dr Pachynski evaluated the immune subsets of the product: largely T and NK-cells. When administered in conjunction with IL-15 in in vitro and humanized murine models, IL-15 significantly increased T-cells’ ability to kill and infiltrate tumor cells. Additionally, several in vivo experiments validated IL-15’s ability to reverse immunosuppression. This interview took place at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.